Karyopharm Therapeutics

Price & Volume

Stats

52W Range	$0.65-$1.95
Market Cap	$87.7M
Shares Short	18M

Financials

Revenue (12 Mos)	$148.4M
Revenue Growth (YoY)	7.7%
Gross Profit (12 Mos)	$151.8M
Diluted EPS	-$1.05

News

Yahoo Finance • last year

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Yahoo Finance • last year

Karyopharm to Participate at Upcoming Investor Conferences

Yahoo Finance • last year

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Yahoo Finance • 2 years ago

Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript

About

CEO	Mr. Richard A. Paulson M.B.A.
Address	85 Wells Avenue, Newton, MA, United States, 02459-3298
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	325